OTPE 425

AMENDMENT TRANSMITTAL LETTER

Docket No.
3749-0112PUS1

Application No.

Filing Date

Examiner

Art Unit

Application No. Filing Date Examiner Art Unit 10/577,008-Conf. #7226 April 25, 2006 Not Yet Assigned 1645

Applicant(s): Toshiharu Suzuki et al.

Invention: MARKER PEPTIDE FOR ALZHEIMER'S DISEASE

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

		CL	AIM	S AS AMENI	DED		
	Claims Remaining After Amendment	Highes Number Previous Paid	r	Number Extra Claims Present		Rate	
Total Claims	15	- 20	=	0	х	50.00	0.00
ndependent Claims	1	- 3	=	0	x	200.00	• 0.00
Multiple Depend	dent Claims (ch	eck if appli	cabl	e)			
Other fee (pleas	se specify):						
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:							0.00
x Large Entity						Small Entit	у
No addition	al fee is require	d for this a	amei	ndment.			
Please char	ge Deposit Acc	ount No.		· iı	n the a	mount of \$	
	copy of this she	_					
A check in t	he amount of \$			is enclo	sed.		
Payment by	credit card. Fe	orm PTO-2	2038	s is attached.			
	r is hereby auth d below. A dup						No. <u>02-2448</u>
x Credit a	ny overpaymer	nt.					
x Charge	any additional fil	ing or appli	catio	on processing	fees re	quired under	37 CFR 1.16 and 1.17.
man						Dated:	January 16, 2007
MaryAnne Arm Attorney Reg. I							
BIRCH, STEW 8110 Gatehous Suite 100 East		H & BIRCI	H, Li	LP			

(703) 205-8000

্দ্লিalls Church, Virginia 22040-0747





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Toshiharu Suzuki et al.

Application No.: 10/577,008

Confirmation No.: 7226

Filed: April 25, 2006

Art Unit: 1645

For: MARKER PEPTIDE FOR ALZHEIMER'S

DISEASE

Examiner: Not Yet Assigned

## **AMENDMENT**

MS Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed November 16, 2007, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

## This Reply includes:

- Amendments to the Specification begin on page 2 of this paper.
- Amendments to the Sequence Listing begin on page 3 of this paper.
- Remarks/Arguments begin on page 4 of this paper.
- An **Appendix** including the paper and CRF disk copy of the Sequence Listing is attached following page 5 of this paper.